Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MXCT vs CTKB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CTKB Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)

CTKB Overall Winner 6-Pillar Tally: MXCT 0 – 5 CTKB (1 Tie) Matrix Metrics: MXCT 2 – 6 CTKB

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas CTKB carries 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin).

  • Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MXCT vs CTKB
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25
CTKB NASDAQ Head-to-Head Winner
Cytek Biosciences, Inc. Common Stock
Laboratory Analytical Instruments
$6.12
-3.16% 1D
Market Cap $826.6M
TTM Revenue $208M
Forward P/E N/M
Beta / 30D Vol 0.71β · 67% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 33.0 Fund 44.0 Flow 60.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.6% over 20 days), RSI 57
RSI-14: 56.9 · SMA20: $5.89 · SMA50: $5.63

6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 5 CTKB)

Columns: Metric · MXCT · CTKB
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.9x 3.8x
2. Growth & Scale CTKB
Revenue Growth (YoY) +48.7% +1.8%
Earnings Growth (YoY) +0.0% +73.5%
TTM Revenue (USD) $34M $208M
Market Cap $132.2M $826.6M
3. Profitability & Quality CTKB
Gross Margin 81.0% 53.4%
Operating Margin -85.5% -22.5%
Net Profit Margin -81.4% -39.1%
Return on Equity (ROE) -16.9% -23.2%
4. Balance Sheet & Cash Flow CTKB
Cash Generation (TTM) -$24M -$14M
Cash Flow Margin -69.2% -6.6%
Net Cash / Leverage $2.2M Net Debt (0.11x D/E) $42M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CTKB
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 0.1% (<1st %ile)
Put/Call OI Skew N/A 0.03x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat CTKB
OpEx & R&D Intensity N/A 75.9% of Rev ($158M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MXCT (2) vs CTKB (6)
Institutional Metric MXCT CTKB Criterion Row Edge
Market Capitalization
Scale
$132.2M $826.6M Larger Scale CTKB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+48.7% +1.8% Higher Growth MXCT
Operating Margin (TTM)
Profitability
-85.5% -22.5% Higher Margin CTKB
Net Profit Margin
Profitability
-81.4% -39.1% Higher Margin CTKB
Return on Equity (ROE)
Capital Efficiency
-16.9% -23.2% Higher ROE MXCT
52-Week Range Position
Momentum
63% ($1–$2) 91% ($3–$6) Stronger Trend CTKB
Beta / 30D Volatility
Risk Regime
1.19β · 96% Vol 0.71β · 67% Vol Lower Realized Risk CTKB
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 48.4 / 100 (HOLD) Higher Composite CTKB
Trailing 12M Revenue (USD)
Operating Scale
$34M $208M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.0% 53.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.9x EV/Rev N/M PEG · 3.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($2.2M Net Debt (0.11x D/E)) -$14M ($42M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CTKB +16.91 pp
MXCT: -4.2% · CTKB: +12.71%
3M Horizon CTKB +39.28 pp
MXCT: -1.44% · CTKB: +37.84%
6M Horizon CTKB +20.89 pp
MXCT: +31.73% · CTKB: +52.62%
1Y Horizon CTKB +35.76 pp
MXCT: -19.41% · CTKB: +16.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MXCT Revenue CTKB Revenue MXCT Op. Margin CTKB Op. Margin Margin Leader
FY2019 $10M N/A -93.7% N/A MXCT
FY2020 $20M $90M -71.6% 14.7% CTKB
FY2021 $20M $130M -84.3% 7.2% CTKB
FY2022 $30M $160M -95.2% -1.1% CTKB
FY2023 $20M $190M -247.7% -14.4% CTKB
FY2024 $20M $200M -230.5% -10.2% CTKB
FY2025 $20M $200M -247.6% -20.0% CTKB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CTKB CONSOLIDATION
16d in phase · OBV ACCUMULATION
Current IV 0.1%
IV Percentile <1st %ile
Put/Call OI Skew 0.03x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CTKB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CTKB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $826.6M market capitalization and -22.5% operating margin.
OpEx & R&D Reinvestment 75.9% of Rev ($158M)
90D Engineering Disclosures 0 Published

Investor FAQ MXCT vs CTKB Key Questions & Quantitative Answers

As of Nov 20, 2026, Cytek Biosciences, Inc. (CTKB) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas CTKB carries 48.4/100 (HOLD) at $6.12 (N/M Forward P/E, -22.5% operating margin). Growth vs. Quality Trade-Off: CTKB earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. MXCT 41.7/100 SELL) and 0.71β · 67% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.

CTKB leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with CTKB at +1.8% YoY revenue growth and +73.5% YoY earnings growth on $208M TTM revenue (53.4% gross margin, -22.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while CTKB shifted +122.2%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus 75.9% of Rev ($158M) (0 disclosures) for CTKB.

MXCT and CTKB trade at balanced relative valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas CTKB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.8x EV/Revenue (-6.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus CTKB (-23.2% ROE) capital efficiency.

In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, CTKB carries 0.1% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.03x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.71β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.